Spectral AI, Inc. (MDAIW) स्टॉक विश्लेषण

कंपनी का अवलोकन

Spectral AI, Inc. operates within the United States market as an artificial intelligence enterprise dedicated to predictive medical diagnostics, utilizing proprietary algorithms to differentiate between fully damaged, partially damaged, and healthy human tissue characteristics. Although the specific sector and industry classifications are not disclosed in the available data, the company's focus on deep learning systems for medical applications positions it within the broader technology and healthcare infrastructure landscape. The entity employs a workforce of 65 individuals to manage its operations and develop its DeepView System platform. With a price-to-book ratio of -3.08 and a trailing twelve-month revenue of $19.65M, the company's valuation metrics and revenue generation indicate a small-cap profile typical of early-stage growth enterprises that prioritize product development over immediate profitability. The negative price-to-book multiple suggests that the market currently values the company's assets below their book value, reflecting the high-risk nature of unprofitable AI development firms.

वित्तीय स्वास्थ्य

The company reported a revenue of $19.65M over the trailing twelve months, yet it posted a net income loss of $-7,571,000 and an EBITDA of $-8,532,000. The significant disparity between the positive revenue of $19.65M and the substantial net loss reveals a cost structure where operating expenses and research and development costs far exceed gross margins, a common characteristic in capital-intensive AI development phases. Free cash flow stands at $-1,379,875, indicating that the company is consuming cash reserves to fund its operations rather than generating surplus liquidity for dividends or debt repayment. Gross margin is calculated at 45.4%, which suggests that the core product pricing retains a healthy portion of revenue before accounting for operational overhead. Conversely, the operating margin sits at -54.9% and the profit margin at -38.5%, demonstrating that the company is burning cash at an aggressive pace to achieve market penetration or technological breakthroughs. On the balance sheet, Spectral AI, Inc. holds $15.39M in cash against $10.09M in debt, providing a net cash position, though the debt-to-equity ratio is not available for direct comparison. The current ratio of 0.94 indicates that the company's current assets are slightly lower than its current liabilities, signaling a potential liquidity constraint where short-term obligations nearly equal available current resources. Additionally, the return on equity is unavailable, while the return on assets is recorded at -32.1%, which mathematically confirms that the management team is currently generating negative returns on the capital invested in the business.

मूल्यांकन आकलन

Trailing P/E and forward P/E ratios are both unavailable (N/A) due to the company's lack of positive earnings, meaning traditional earnings-based valuation multiples cannot be applied to assess future earnings trajectory. The price-to-book ratio is recorded at -3.08, a negative figure that indicates the market values the company at a price significantly below its net asset book value, often seen in distressed or unprofitable technology firms. Price-to-sales and EV/EBITDA metrics are also unavailable, suggesting that analysts must rely on alternative methods like discounted cash flow or asset-based valuation rather than relative multiples for comparison. The stock's 52-week trading range spans from a low of $0.58 to a high of $0.59, creating an extremely narrow band of volatility within a one-cent spread. Given this tight range, the current market price effectively trades at a premium relative to the 52-week low but remains below the 52-week high, reflecting high sensitivity to minor market fluctuations. The beta coefficient is 0.91, which implies that the stock's price volatility moves in tandem with the broader market index, exhibiting slightly less sensitivity than the market average but still maintaining a standard risk profile for large-cap equities.

Growth & Income

Revenue growth year-over-year is recorded at -46.3%, while earnings growth is unavailable due to the company's continued losses. The negative revenue growth indicates a contraction in sales, whereas the inability to calculate earnings growth stems from the persistent net losses rather than a divergence in growth rates between the top line and the bottom line. The company does not pay dividends, as evidenced by the unavailable dividend yield and payout ratio figures, which means all available capital is retained for reinvestment into the DeepView System and future growth initiatives rather than being distributed to shareholders. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of income distribution, highlighting a strategy focused entirely on survival and product scaling in a highly competitive medical AI sector.